Literature DB >> 6329083

Synergistic antiviral effects of antiherpes compounds and human leukocyte interferon on varicella-zoster virus in vitro.

M Baba, M Ito, S Shigeta, E De Clercq.   

Abstract

The four antiherpes compounds acyclovir, adenine arabinoside, bromovinyldeoxyuridine, and phosphonoformic acid showed an additive to synergistic effect with human leukocyte interferon in inhibiting focus formation by three different strains of varicella-zoster virus in human embryonic fibroblasts.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6329083      PMCID： PMC185568          DOI： 10.1128/AAC.25.4.515

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Antagonists of nucleic acid derivatives. VIII. Synergism in combinations of biochemically related antimetabolites.

Authors:  G B ELION; S SINGER; G H HITCHINGS
Journal:  J Biol Chem       Date:  1954-06       Impact factor: 5.157

2.  Synergistic effect of 5'-amino-5'-deoxythymidine and 5-iodo-2'-deoxyuridine against Herpes Simplex virus infections in vitro.

Authors:  P H Fischer; J J Lee; M S Chen; T S Lin; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1979-12-01       Impact factor: 5.858

3.  Differential affinities of 5-(2-halogenovinyl)-2'-deoxyuridines for deoxythymidine kinases of various origins.

Authors:  Y C Cheng; G Dutschman; E De Clercq; A S Jones; S G Rahim; G Verhelst; R T Walker
Journal:  Mol Pharmacol       Date:  1981-07       Impact factor: 4.436

4.  In vitro susceptibility of varicella-zoster virus to acyclovir.

Authors:  K K Biron; G B Elion
Journal:  Antimicrob Agents Chemother       Date:  1980-09       Impact factor: 5.191

5.  Combined antiviral effect of DNA inhibitors on Herpes simplex virus multiplication.

Authors:  R Wigand; M Hassinger
Journal:  Med Microbiol Immunol       Date:  1980       Impact factor: 3.402

6.  Combination chemotherapy: interaction of 5-methoxymethyldeoxyuridine with adenine arabinoside, 5-ethyldeoxyuridine, 5-iododeoxyuridine, and phosphonoacetic acid against herpes simplex virus types 1 and 2.

Authors:  N K Ayisi; V S Gupta; J B Meldrum; A K Taneja; L A Babiuk
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

7.  Combined antiviral effect of interferon and acyclovir on herpes simplex virus types 1 and 2.

Authors:  T L Stanwick; R F Schinazi; D E Campbell; A J Nahmias
Journal:  Antimicrob Agents Chemother       Date:  1981-04       Impact factor: 5.191

8.  Inhibition of human herpesviruses by combination of acyclovir and human leukocyte interferon.

Authors:  M J Levin; P L Leary
Journal:  Infect Immun       Date:  1981-06       Impact factor: 3.441

9.  Effect of acyclovir combined with other antiherpetic agents on varicella zoster virus in vitro.

Authors:  K K Biron; G B Elion
Journal:  Am J Med       Date:  1982-07-20       Impact factor: 4.965

10.  Comparative efficacy of antiherpes drugs against various strains of varicella-zoster virus.

Authors:  S Shigeta; T Yokota; T Iwabuchi; M Baba; K Konno; M Ogata; E De Clercq
Journal:  J Infect Dis       Date:  1983-03       Impact factor: 5.226
  10 in total
  12 in total

Review 1.  Infectious disease therapy in the 1990s. Where are we heading?

Authors:  M Rozenberg-Arska; M R Visser
Journal:  Drugs       Date:  1992-05       Impact factor: 9.546

2.  Activity of different antiviral drug combinations against human cytomegalovirus replication in vitro.

Authors:  R Snoeck; G Andrei; D Schols; J Balzarini; E De Clercq
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-12       Impact factor: 3.267

3.  Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon.

Authors:  K L Hartshorn; M W Vogt; T C Chou; R S Blumberg; R Byington; R T Schooley; M S Hirsch
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

4.  Nucleoside metabolism in herpes simplex virus-infected cells following treatment with interferon and acyclovir, a possible mechanism of synergistic antiviral activity.

Authors:  W J O'Brien; E C Coe; J L Taylor
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

5.  Sodium lauryl sulfate increases the efficacy of a topical formulation of foscarnet against herpes simplex virus type 1 cutaneous lesions in mice.

Authors:  J Piret; A Désormeaux; H Cormier; J Lamontagne; P Gourde; J Juhász; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

6.  Synergistic effect of human leukocyte interferon and nonoxynol 9 against herpes simplex virus type 2.

Authors:  F Rapp; H Wrzos
Journal:  Antimicrob Agents Chemother       Date:  1985-09       Impact factor: 5.191

7.  1,1,3-Trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine (TTD) derivatives: a new class of nonnucleoside human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitors with anti-HIV-1 activity.

Authors:  M Witvrouw; M E Arranz; C Pannecouque; R Declercq; H Jonckheere; J C Schmit; A M Vandamme; J A Diaz; S T Ingate; J Desmyter; R Esnouf; L Van Meervelt; S Vega; J Balzarini; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

8.  SRR-SB3, a disulfide-containing macrolide that inhibits a late stage of the replicative cycle of human immunodeficiency virus.

Authors:  M Witvrouw; J Balzarini; C Pannecouque; S Jhaumeer-Laulloo; J A Esté; D Schols; P Cherepanov; J C Schmit; Z Debyser; A M Vandamme; J Desmyter; S R Ramadas; E de Clercq
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

9.  Ribavirin antagonizes inhibitory effects of pyrimidine 2',3'-dideoxynucleosides but enhances inhibitory effects of purine 2',3'-dideoxynucleosides on replication of human immunodeficiency virus in vitro.

Authors:  M Baba; R Pauwels; J Balzarini; P Herdewijn; E De Clercq; J Desmyter
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

Review 10.  Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  A J Wagstaff; D Faulds; K L Goa
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.